Peng Ding

机构：Shanghai University of Electric Power, China General Nuclear Power Corporation (China), PLA 306 Hospital · ORCID：0000-0003-0424-0186

发表论文 54 篇 · 总被引 802 次 · h-index 13

代表论文

• Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome (2022 · European Journal of Pharmacology · 被引 246)
• Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway (2023 · Critical Care · 被引 59)
• Wearable transcutaneous electrical acupoint stimulation bracelet for prevention of postoperative nausea and vomiting in patients undergoing hysteroscopic surgery: a randomised controlled trial (2022 · British Journal of Anaesthesia · 被引 24)
• BMPER alleviates ischemic brain injury by protecting neurons and inhibiting neuroinflammation via Smad3‐Akt‐Nrf2 pathway (2021 · CNS Neuroscience & Therapeutics · 被引 12)
• Advanced lithium-ion battery health state estimation using a Bayesian optimization hybrid neural network model (2025 · Journal of Energy Storage · 被引 11)
• New developments in non-exosomal and exosomal ncRNAs in coronary artery disease (2022 · Epigenomics · 被引 10)